BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 11, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 11, 1999
View Archived Issues
Pharming: Q4 and year-end results
Read More
Xoma: year-end 1998 highlights
Read More
Cell Therapeutics anticipates oncology milestones for 1999
Read More
Nesiritide improves symptoms, hemodynamics in both moderate and severe CHF
Read More
Results from brasofensine trial in Parkinson's disease released
Read More
Potential CNS effects of insulin in humans
Read More
Cypress Bioscience and Fresenius sign definitive agreement for Prosorba Column
Read More
Greater reductions in LDL cholesterol lead to fewer cardiac events
Read More
Transgene initiates second phase II trial with Vero-IL-2 in mesothelioma
Read More
Viable myocardium can be detected using SHU-563A for contrast enhancement
Read More
Bristol-Myers Squibb completes U.S. filing for Orzel, the first oral treatment for colon cancer
Read More
Dual vasopeptidase inhibition provides considerable therapeutic benefit in heart failure
Read More
Cor Therapeutics presents cromafiban, the first orally active once-daily gpIIb/IIIa antagonist
Read More
Health Canada approves Viagra
Read More
Results of phase II FROST study of lefradafiban presented at ACC
Read More
Astra presents results of first human trial of AR-C69931MX at ACC meeting
Read More
Improved non-nucleoside HIV-1 RT inhibitors in development at Boehringer Ingelheim
Read More
Heterocyclic factor Xa inhibitors disclosed by Zeneca
Read More
Inhibitors of metallo-beta-lactamases discovered at SmithKline Beecham
Read More
Novel neuraminidase inhibitors described by U. of Florida
Read More
Protein prenylation inhibitors under study at Pierre Fabre for use in cancer, etc.
Read More
Novel class of GABA-A receptor ligands for cognitive disorders from Merck
Read More
Eplerenone, a novel SARA from Searle, is effective in the treatment of heart failure
Read More
WHI-P154 enhances the response of mast cells in infections
Read More
Vertex initiates phase I clinical trial with VX-745
Read More
Resolution Pharmaceuticals initiates phase I/II study of lead oncology imaging product
Read More
Repligen to develop novel treatment for autism; clinical trials slated to begin this year
Read More
DDE-131, a potential treatment for mast cell-mediated hypersensitivity
Read More
